MK-2866 and Telmisartan Interaction

Avoid
Mechanism-based 64% confidence

MK-2866 and Telmisartan have a potentially harmful interaction with 64% confidence. Both MK-2866 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Telmisartan

Angiotensin II Receptor Blocker | Cardiac Protection On Cycle

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling.

Half-life: ~24 hours Typical dose: 20-80 mg/day cardiovascular
ppar gamma blood pressure raisinghepatotoxicinsulin sensitizingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate

Shared Safety Flags

2x 2 hepatotoxic compounds (MK-2866, Telmisartan). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take MK-2866 with Telmisartan?

Combining MK-2866 with Telmisartan is not recommended. Both MK-2866 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is MK-2866 and Telmisartan safe together?

This combination carries significant risk. Both MK-2866 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between MK-2866 and Telmisartan?

Both MK-2866 and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time MK-2866 and Telmisartan?

MK-2866 has a half-life of ~24 hours and Telmisartan has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: MK-2866 vs Telmisartan

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.